Enteric-coated charcoal as a means of blinding studies comparing bismuth and H2-receptor antagonists

S. Yates, C. Barnett, W. L. Peterson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Clinical trials comparing H2-receptor antagonists and bismuth-containing regimens in ulcer healing, ulcer relapse, or dyspepsia have not been double- blind, because bismuth darkens stools. This study was designed to determine whether enteric-coated charcoal could darken stools of subjects taking an H2- receptor antagonist without interfering with absorption of the drug. Twelve healthy volunteers participated in a randomized, double-blind, crossover trial of oral ranitidine (300 mg at bedtime) alone, ranitidine plus bismuth (30 ml Pepto-Bismol four times daily), and ranitidine plus enteric-coated charcoal (four tablets daily). Mean stool colors both with ranitidine plus charcoal and with ranitidine plus bismuth were significantly darker than with ranitidine alone, but were not significantly different from each other. Blood levels of ranitidine during the 10 h after its administration did not differ significantly among the three regimens. We conclude that enteric-coated charcoal can be used to blind clinical trials comparing an H2-receptor antagonist (e.g., ranitidine) and a bismuth regimen.

Original languageEnglish (US)
Pages (from-to)981-984
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume87
Issue number8
StatePublished - 1992

Fingerprint

Histamine H2 Receptors
Bismuth
Ranitidine
Charcoal
Ulcer
Clinical Trials
Dyspepsia
Cross-Over Studies
Tablets
Healthy Volunteers
Color
Recurrence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Enteric-coated charcoal as a means of blinding studies comparing bismuth and H2-receptor antagonists. / Yates, S.; Barnett, C.; Peterson, W. L.

In: American Journal of Gastroenterology, Vol. 87, No. 8, 1992, p. 981-984.

Research output: Contribution to journalArticle

@article{6f1486b146214bac85848f5d020bd51d,
title = "Enteric-coated charcoal as a means of blinding studies comparing bismuth and H2-receptor antagonists",
abstract = "Clinical trials comparing H2-receptor antagonists and bismuth-containing regimens in ulcer healing, ulcer relapse, or dyspepsia have not been double- blind, because bismuth darkens stools. This study was designed to determine whether enteric-coated charcoal could darken stools of subjects taking an H2- receptor antagonist without interfering with absorption of the drug. Twelve healthy volunteers participated in a randomized, double-blind, crossover trial of oral ranitidine (300 mg at bedtime) alone, ranitidine plus bismuth (30 ml Pepto-Bismol four times daily), and ranitidine plus enteric-coated charcoal (four tablets daily). Mean stool colors both with ranitidine plus charcoal and with ranitidine plus bismuth were significantly darker than with ranitidine alone, but were not significantly different from each other. Blood levels of ranitidine during the 10 h after its administration did not differ significantly among the three regimens. We conclude that enteric-coated charcoal can be used to blind clinical trials comparing an H2-receptor antagonist (e.g., ranitidine) and a bismuth regimen.",
author = "S. Yates and C. Barnett and Peterson, {W. L.}",
year = "1992",
language = "English (US)",
volume = "87",
pages = "981--984",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Enteric-coated charcoal as a means of blinding studies comparing bismuth and H2-receptor antagonists

AU - Yates, S.

AU - Barnett, C.

AU - Peterson, W. L.

PY - 1992

Y1 - 1992

N2 - Clinical trials comparing H2-receptor antagonists and bismuth-containing regimens in ulcer healing, ulcer relapse, or dyspepsia have not been double- blind, because bismuth darkens stools. This study was designed to determine whether enteric-coated charcoal could darken stools of subjects taking an H2- receptor antagonist without interfering with absorption of the drug. Twelve healthy volunteers participated in a randomized, double-blind, crossover trial of oral ranitidine (300 mg at bedtime) alone, ranitidine plus bismuth (30 ml Pepto-Bismol four times daily), and ranitidine plus enteric-coated charcoal (four tablets daily). Mean stool colors both with ranitidine plus charcoal and with ranitidine plus bismuth were significantly darker than with ranitidine alone, but were not significantly different from each other. Blood levels of ranitidine during the 10 h after its administration did not differ significantly among the three regimens. We conclude that enteric-coated charcoal can be used to blind clinical trials comparing an H2-receptor antagonist (e.g., ranitidine) and a bismuth regimen.

AB - Clinical trials comparing H2-receptor antagonists and bismuth-containing regimens in ulcer healing, ulcer relapse, or dyspepsia have not been double- blind, because bismuth darkens stools. This study was designed to determine whether enteric-coated charcoal could darken stools of subjects taking an H2- receptor antagonist without interfering with absorption of the drug. Twelve healthy volunteers participated in a randomized, double-blind, crossover trial of oral ranitidine (300 mg at bedtime) alone, ranitidine plus bismuth (30 ml Pepto-Bismol four times daily), and ranitidine plus enteric-coated charcoal (four tablets daily). Mean stool colors both with ranitidine plus charcoal and with ranitidine plus bismuth were significantly darker than with ranitidine alone, but were not significantly different from each other. Blood levels of ranitidine during the 10 h after its administration did not differ significantly among the three regimens. We conclude that enteric-coated charcoal can be used to blind clinical trials comparing an H2-receptor antagonist (e.g., ranitidine) and a bismuth regimen.

UR - http://www.scopus.com/inward/record.url?scp=0026724183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026724183&partnerID=8YFLogxK

M3 - Article

C2 - 1642222

AN - SCOPUS:0026724183

VL - 87

SP - 981

EP - 984

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -